BACKGROUND: The synergy between herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus type 1 (HIV-1) is well known, but lack of knowledge about the epidemiology of HSV-2 acquisition in HIV-1-discordant couples hampers development of HSV-2 prevention interventions that could reduce HIV-1 transmission. METHODS: HIV-1-discordant couples were enrolled in Nairobi, Kenya, and followed for up to 2 years. HSV-2 status was determined using HerpeSelect HSV-2 ELISA. Correlates of prevalence and incidence were assessed. RESULTS.: Of 469 HIV-1-discordant couples, at baseline, 353 (75.3%) were affected by HSV-2, of which 189 (53.5%) were concordantly HSV-2 seropositive and 164 (46.5%) were HSV-2-discordant. Prevalence was lowest among HIV-1-uninfected men (39.9%) compared to HIV-1-infected women (64.8%), HIV-1-infected men (66.7%), and HIV-1-uninfected women (68.5%). During follow-up, HSV-2 seroincidence was 14.9 per 100 person-years. Incidence was 1.6-fold higher among females compared to males (95% confidence interval [CI], 1.00-2.48) and 2.5-fold higher in HIV-1-infected compared to uninfected women (95% CI, 1.12-5.74). At least 30% of incident HSV-2 infections originated from an outside partner. CONCLUSIONS: The high HSV-2 prevalence and incidence in HIV-1-discordant couples in sub-Saharan Africa suggest HSV-2 treatment and prevention could be an effective targeted strategy to reduce HSV-2 and HIV-1 transmission in this high-risk population.
BACKGROUND: The synergy between herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus type 1 (HIV-1) is well known, but lack of knowledge about the epidemiology of HSV-2 acquisition in HIV-1-discordant couples hampers development of HSV-2 prevention interventions that could reduce HIV-1 transmission. METHODS:HIV-1-discordant couples were enrolled in Nairobi, Kenya, and followed for up to 2 years. HSV-2 status was determined using HerpeSelect HSV-2 ELISA. Correlates of prevalence and incidence were assessed. RESULTS.: Of 469 HIV-1-discordant couples, at baseline, 353 (75.3%) were affected by HSV-2, of which 189 (53.5%) were concordantly HSV-2 seropositive and 164 (46.5%) were HSV-2-discordant. Prevalence was lowest among HIV-1-uninfectedmen (39.9%) compared to HIV-1-infectedwomen (64.8%), HIV-1-infectedmen (66.7%), and HIV-1-uninfectedwomen (68.5%). During follow-up, HSV-2 seroincidence was 14.9 per 100 person-years. Incidence was 1.6-fold higher among females compared to males (95% confidence interval [CI], 1.00-2.48) and 2.5-fold higher in HIV-1-infected compared to uninfected women (95% CI, 1.12-5.74). At least 30% of incident HSV-2 infections originated from an outside partner. CONCLUSIONS: The high HSV-2 prevalence and incidence in HIV-1-discordant couples in sub-Saharan Africa suggest HSV-2 treatment and prevention could be an effective targeted strategy to reduce HSV-2 and HIV-1 transmission in this high-risk population.
Authors: R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn Journal: Lancet Date: 2001-04-14 Impact factor: 79.321
Authors: F X Mbopi-Kéou; G Grésenguet; P Mayaud; H A Weiss; R Gopal; M Matta; J L Paul; D W Brown; R J Hayes; D C Mabey; L Bélec Journal: J Infect Dis Date: 2000-09-08 Impact factor: 5.226
Authors: A Wald; A G Langenberg; K Link; A E Izu; R Ashley; T Warren; S Tyring; J M Douglas; L Corey Journal: JAMA Date: 2001-06-27 Impact factor: 56.272
Authors: Jared M Baeten; R Scott McClelland; Lawrence Corey; Julie Overbaugh; Ludo Lavreys; Barbra A Richardson; Anna Wald; Kishorchandra Mandaliya; Job J Bwayo; Joan K Kreiss Journal: J Infect Dis Date: 2004-04-02 Impact factor: 5.226
Authors: Oliver Laeyendecker; Charla Henson; Ronald H Gray; Ruby H-N Nguyen; Bobbi Jo Horne; Maria J Wawer; David Serwadda; Noah Kiwanuka; Rhoda Ashley Morrow; Wayne Hogrefe; Thomas C Quinn Journal: J Clin Microbiol Date: 2004-04 Impact factor: 5.948
Authors: Steven J Reynolds; Arun R Risbud; Mary E Shepherd; Jonathan M Zenilman; Ronald S Brookmeyer; Ramesh S Paranjape; Anand D Divekar; Raman R Gangakhedkar; Manisha V Ghate; Robert C Bollinger; Sanjay M Mehendale Journal: J Infect Dis Date: 2003-04-23 Impact factor: 5.226
Authors: Lawrence Corey; Anna Wald; Raj Patel; Stephen L Sacks; Stephen K Tyring; Terri Warren; John M Douglas; Jorma Paavonen; R Ashley Morrow; Karl R Beutner; Leonid S Stratchounsky; Gregory Mertz; Oliver N Keene; Helen A Watson; Dereck Tait; Mauricio Vargas-Cortes Journal: N Engl J Med Date: 2004-01-01 Impact factor: 91.245
Authors: Brandon L Guthrie; Andrea Introini; Alison C Roxby; Robert Y Choi; Rose Bosire; Barbara Lohman-Payne; Taha Hirbod; Carey Farquhar; Kristina Broliden Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: Britta L Jewell; Ide Cremin; Michael Pickles; Connie Celum; Jared M Baeten; Sinead Delany-Moretlwe; Timothy B Hallett Journal: PLoS One Date: 2015-01-23 Impact factor: 3.240